+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Statins, Ventricular Arrhythmias and Heart Rate Variability in Patients with Implantable Cardioverter Defibrillators and Coronary Heart Disease


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The aim of this study was to evaluate whether the incidence of ventricular arrhythmias and heart rate variability were influenced by statin treatment and lipid levels in patients treated with an implantable cardioverter defibrillator (ICD). Heart rate variability measurements were performed in 86 patients with coronary heart disease and an ICD implant. The number of events with ventricular fibrillation and ventricular tachycardia were recorded during a 12-month period. This study lends little support for an antiarrhythmic effect of statins or any relation between plasma lipids and lipoproteins and malignant ventricular arrhythmias in patients with an ICD.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Antiatherothrombotic Properties of Statins

            • Record: found
            • Abstract: found
            • Article: not found

            Beyond lipid lowering: the role of statins in vascular protection.

            James Liao (2002)
            The introduction of the hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in 1987 was a major advance in the prevention and treatment of cardiovascular disease. Several landmark clinical trials have demonstrated the benefit of lipid lowering with statins for the primary and secondary prevention of coronary heart disease (CHD), namely The Scandinavian Simvastatin Survival Study (4S), Cholesterol And Recurrent Events (CARE), Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), West of Scotland Coronary Prevention Study (WOSCOPS) and Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Although it is widely accepted that the majority of clinical benefit obtained with statins is a direct result of their lipid-lowering properties, these agents appear to display additional cholesterol-independent or pleiotropic effects on various aspects of cardiovascular disease, including improving endothelial function, decreasing vascular inflammation and enhancing plaque stability. Although the full impact of statin therapy on each of these processes is not fully understood, ongoing studies with current and new statins are likely to shed further light on the potential cholesterol-independent benefits of these agents.
              • Record: found
              • Abstract: not found
              • Article: not found

              Heart Protection Study


                Author and article information

                S. Karger AG
                September 2005
                04 October 2005
                : 104
                : 4
                : 210-214
                aDepartment of Cardiology, Cardiovascular Research Center, and bDepartment of Nephrology, Aalborg Hospital, Århus University Hospital, cCenter for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, and dDepartment of Cardiology, Skejby Hospital, Århus University Hospital, Århus, Denmark
                88175 Cardiology 2005;104:210–214
                © 2005 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                : 29 January 2005
                : 18 April 2005
                Page count
                Figures: 1, Tables: 3, References: 18, Pages: 5
                Arrhythmias and Electrophysiology

                General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
                Heart rate variability,Coronary heart disease,HMG-CoA reductase inhibitors,Plasma lipids,Implanted cardioverter defibrillator


                Comment on this article